Characteristics of AML patient samples
Sample . | Source . | Assay . | Blasts, % . | Cytogenetics . | Previous treatments and responses . |
|---|---|---|---|---|---|
| AML-1 | PB | Annexin V | 82 | 46,XY, diploid, poor | Resistant to Ara-C + daunorubicin, topotecan + Ara-C + mitoxantrone, and gemtuzumab ozogamicin |
| AML-2 | PB | Annexin V | 85 | Diploid | Untreated |
| AML-3 | BM | Annexin V, colony | 99 | Poor | Resistant to topotecan + Ara-C + gemtuzumab ozogamicin; achieved CR with mitoxantrone + VP-16; then relapsed; resistant to SAHA |
| AML-5 | PB | Annexin V | 90 | Poor | Resistant to Ara-C + mitoxantrone, Bryo + Ara-C, and DAC + VPA; achieved CR with Ara-C, CI × 7 d + mitoxantrone d 5-7 + FA twice daily × 5 d; then relapsed |
| AML-6 | BM | Annexin V, colony | 81 | Good | Untreated |
| AML-7 | BM | Colony | 85 | Poor | Achieved CR with FAMP + HDAC; then relapsed |
| AML-8 | BM | Colony | 67 | Diploid | Resistant to Ara-C + Ida, HDAC, cyclophosphamide + VP-16, and rosiglitazone + bexarotene |
| AML-9 | BM | Colony | 90 | Poor | Achieved CR with Ida + Ara-C and allotransplantation; then relapsed; resistant to mitoxantrone + VP-16, FA twice daily × 5 d, and DAC + VPA |
| AML-10 | PB | Annexin V, WB | 93 | 46,XX, diploid | Resistant to CLOFA + LDAC, XL119, AVE9633, and IA |
| AML-11 | PB | Annexin V, WB, combination | 98 | 46,XY, diploid | Achieved CR with IA; resistant to mitoxantrone, etoposide + cytarabine + oral CEP-701, and L-001281814 |
| AML-12 | BM | Annexin V, WB | 94 | t(9;11) etc, poor | Refractory AML with unknown treatment history |
| AML-13 | PB | Annexin V, WB, combination | 96 | inv(7) etc | Resistant to IA, Ara-C, L-001281814, and FA twice daily × 5 d + gemtuzumab ozogamicin |
| AML-14 | PB | Annexin V, WB, combination | 95 | 48,XX, +6, +8[7] | Resistant to IA, gemtuzumab ozogamicin, and BCH |
| AML-15 | PB | Annexin V, WB | 64 | 46,XY[20], diploid | Untreated |
| AML-16 | PB | Combination | 98 | 46,XX[28] | Resistant to IA, fludarabine + Ara-C, mitoxantrone + Ara-C + VP-16, and XKR69R |
Sample . | Source . | Assay . | Blasts, % . | Cytogenetics . | Previous treatments and responses . |
|---|---|---|---|---|---|
| AML-1 | PB | Annexin V | 82 | 46,XY, diploid, poor | Resistant to Ara-C + daunorubicin, topotecan + Ara-C + mitoxantrone, and gemtuzumab ozogamicin |
| AML-2 | PB | Annexin V | 85 | Diploid | Untreated |
| AML-3 | BM | Annexin V, colony | 99 | Poor | Resistant to topotecan + Ara-C + gemtuzumab ozogamicin; achieved CR with mitoxantrone + VP-16; then relapsed; resistant to SAHA |
| AML-5 | PB | Annexin V | 90 | Poor | Resistant to Ara-C + mitoxantrone, Bryo + Ara-C, and DAC + VPA; achieved CR with Ara-C, CI × 7 d + mitoxantrone d 5-7 + FA twice daily × 5 d; then relapsed |
| AML-6 | BM | Annexin V, colony | 81 | Good | Untreated |
| AML-7 | BM | Colony | 85 | Poor | Achieved CR with FAMP + HDAC; then relapsed |
| AML-8 | BM | Colony | 67 | Diploid | Resistant to Ara-C + Ida, HDAC, cyclophosphamide + VP-16, and rosiglitazone + bexarotene |
| AML-9 | BM | Colony | 90 | Poor | Achieved CR with Ida + Ara-C and allotransplantation; then relapsed; resistant to mitoxantrone + VP-16, FA twice daily × 5 d, and DAC + VPA |
| AML-10 | PB | Annexin V, WB | 93 | 46,XX, diploid | Resistant to CLOFA + LDAC, XL119, AVE9633, and IA |
| AML-11 | PB | Annexin V, WB, combination | 98 | 46,XY, diploid | Achieved CR with IA; resistant to mitoxantrone, etoposide + cytarabine + oral CEP-701, and L-001281814 |
| AML-12 | BM | Annexin V, WB | 94 | t(9;11) etc, poor | Refractory AML with unknown treatment history |
| AML-13 | PB | Annexin V, WB, combination | 96 | inv(7) etc | Resistant to IA, Ara-C, L-001281814, and FA twice daily × 5 d + gemtuzumab ozogamicin |
| AML-14 | PB | Annexin V, WB, combination | 95 | 48,XX, +6, +8[7] | Resistant to IA, gemtuzumab ozogamicin, and BCH |
| AML-15 | PB | Annexin V, WB | 64 | 46,XY[20], diploid | Untreated |
| AML-16 | PB | Combination | 98 | 46,XX[28] | Resistant to IA, fludarabine + Ara-C, mitoxantrone + Ara-C + VP-16, and XKR69R |
WB, XIAP, Mcl-1, and caspase-3 protein levels were determined by Western blot after cells were treated with triptolide for 24 hours; and combination, cells were treated in vitro with triptolide in combination with doxorubicin, gemtuzumab ozogamicin, or Ara-C.
PB indicates peripheral blood; BM, bone marrow; SAHA, suberoylanilide hydroxamic acid; Bryo, bryostatin; DAC, dacitabine; VPA, valproic acid; FA, fludarabine + Ara-C; FAMP, fludarabine; HDAC, high-dose Ara-C; Ida, idarubicin; CLOFA, clofarabine; LDAC, low-dose Ara-C; IA, Ida—Ara-C; etc, other cytogenetic abnormalities; and BCH, troxacitabine.